Allarity Therapeutics, Inc. (NASDAQ:ALLR) Short Interest Update

Allarity Therapeutics, Inc. (NASDAQ:ALLR) was the recipient of a significant increase in short interest during the month of January. As of January 15th, there was short interest totalling 547,000 shares, an increase of 102.8% from the December 31st total of 269,700 shares. Based on an average daily trading volume, of 1,520,000 shares, the short-interest ratio is presently 0.4 days. Currently, 13.8% of the shares of the stock are short sold.

Allarity Therapeutics Trading Down 16.3 %

Allarity Therapeutics stock opened at $1.18 on Friday. Allarity Therapeutics has a 1 year low of $0.90 and a 1 year high of $288.00. The firm’s 50 day moving average price is $1.11 and its 200-day moving average price is $2.52.

Allarity Therapeutics Company Profile

Allarity Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme.